| Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials M Di Maio, C Gallo, NB Leighl, MC Piccirillo, G Daniele, F Nuzzo, ... Journal of Clinical oncology 33 (8), 910-915, 2015 | 451 | 2015 |
| Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial S Pignata, G Scambia, D Katsaros, C Gallo, E Pujade-Lauraine, ... The lancet oncology 15 (4), 396-405, 2014 | 410 | 2014 |
| First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts, V Gebbia, P Maione, ... J Clin Oncol 30 (24), 3002-3011, 2012 | 276 | 2012 |
| Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and … A Morabito, MC Piccirillo, F Falasconi, G De Feo, A Del Giudice, J Bryce, ... The oncologist 14 (4), 378-390, 2009 | 234 | 2009 |
| Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive … U Wagner, C Marth, R Largillier, J Kaern, C Brown, M Heywood, ... British journal of cancer 107 (4), 588-591, 2012 | 219 | 2012 |
| Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase … S Pignata, D Lorusso, G Scambia, D Sambataro, S Tamberi, S Cinieri, ... The Lancet Oncology 16 (5), 561-568, 2015 | 170 | 2015 |
| Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a … B Vincenzi, M Di Maio, M Silletta, L D’Onofrio, C Spoto, MC Piccirillo, ... PloS one 10 (7), e0133488, 2015 | 150 | 2015 |
| Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial F Perrone, MC Piccirillo, PA Ascierto, C Salvarani, R Parrella, AM Marata, ... Journal of translational medicine 18 (1), 405, 2020 | 146 | 2020 |
| The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy F Perrone, C Jommi, M Di Maio, A Gimigliano, C Gridelli, S Pignata, ... Annals of oncology 27 (12), 2224-2229, 2016 | 129 | 2016 |
| Target-based therapies in breast cancer: current status and future perspectives N Normanno, A Morabito, A De Luca, MC Piccirillo, M Gallo, MR Maiello, ... Endocrine-related cancer 16 (3), 675, 2009 | 112 | 2009 |
| The importance of understanding the stages of COVID-19 in treatment and trials. DO Griffin, D Brennan-Rieder, B Ngo, P Kory, M Confalonieri, L Shapiro, ... AIDS reviews 23 (1), 2021 | 103 | 2021 |
| EGFR mutations in lung cancer: from tissue testing to liquid biopsy F Fenizia, A De Luca, R Pasquale, A Sacco, L Forgione, M Lambiase, ... Future oncology 11 (11), 1611-1623, 2015 | 97 | 2015 |
| Treatment of small cell lung cancer A Morabito, G Carillio, G Daniele, MC Piccirillo, A Montanino, R Costanzo, ... Critical reviews in oncology/hematology 91 (3), 257-270, 2014 | 97 | 2014 |
| Angiogenesis inhibitors in NSCLC A Manzo, A Montanino, G Carillio, R Costanzo, C Sandomenico, ... International Journal of Molecular Sciences 18 (10), 2021, 2017 | 92 | 2017 |
| Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results V Granata, R Fusco, M Piccirillo, R Palaia, A Petrillo, S Lastoria, F Izzo International Journal of Surgery 18, 230-236, 2015 | 88 | 2015 |
| Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials M Di Maio, N Lama, A Morabito, EF Smit, V Georgoulias, K Takeda, ... European Journal of Cancer 46 (4), 735-743, 2010 | 87 | 2010 |
| Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2. 16, ENGOT-Ov1, GCIG … S Pignata, G Scambia, A Bologna, S Signoriello, IB Vergote, U Wagner, ... Journal of Clinical Oncology 35 (29), 3347-3353, 2017 | 85 | 2017 |
| Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ... The Lancet Oncology 19 (4), 474-485, 2018 | 83 | 2018 |
| Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial E Rossi, A Morabito, F Di Rella, G Esposito, A Gravina, V Labonia, ... Journal of Clinical Oncology 27 (19), 3192-3197, 2009 | 80 | 2009 |
| Immunotherapy in small cell lung cancer G Esposito, G Palumbo, G Carillio, A Manzo, A Montanino, V Sforza, ... Cancers 12 (9), 2522, 2020 | 76 | 2020 |
